Evidence map›Paper›PMID 33786039›Full record

ArticleFrontiers in immunology2021

Stem Cell Factor Neutralization Protects From Severe Anaphylaxis in a Murine Model of Food Allergy.

Catherine Ptaschinski, Andrew J Rasky, Wendy Fonseca, Nicholas W Lukacs

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Research Advances in Mast Cell Biology and Their Translation Into Novel Therapies for Anaphylaxis.The journal of allergy and clinical immunology. In practice · 2023
    Review
  4. Article
  5. Article
  6. Human Lung Mast Cells: Therapeutic Implications in Asthma.International journal of molecular sciences · 2022
    Review
  7. KIT as a master regulator of the mast cell lineage.The Journal of allergy and clinical immunology · 2022
    Review
  8. Review
  9. New Biomarkers in Anaphylaxis (Beyond Tryptase).Current treatment options in allergy · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Catherine PtaschinskiDepartment of Pathology, Ann Arbor, MI, United States.
Andrew J RaskyDepartment of Pathology, Ann Arbor, MI, United States.
Wendy FonsecaDepartment of Pathology, Ann Arbor, MI, United States.
Nicholas W LukacsDepartment of Pathology, Ann Arbor, MI, United States.
University of Michigan–Ann Arbor · US

Funding

Viral and allergen-driven immunity in chronic lung diseaseR35HL150682 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Nicholas W Lukacs · 2020 to 2026
$4.8M
Inhibition of Stem Cell Factor in Allergic AsthmaR01HL138013 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUKACS, NICHOLAS W · 2018 to 2019
$947k
NHLBI NIH HHS R01 HL138013NHLBI NIH HHS R35 HL150682
6 · The paper itself

Abstract

Food allergy is a growing public health problem with ~15 million people affected in the United States. In allergic food disease, IgE on mast cells bind to ingested antigens leading to the activation and degranulation of mast cells. Stem cell factor (SCF) is mast cell growth and activation factor that is required for peripheral tissue mast cells. We targeted a specific isoform of SCF, the larger 248 amino acid form, that drives peripheral tissue mast cell differentiation using a specific monoclonal antibody in a model of food allergy. Ovalbumin sensitized and intragastrically challenged mice were monitored for symptoms of anaphylaxis including respiratory distress, diarrhea, and a reduction in body temperature. During the second week of challenges, allergic mice were injected with an antibody to block SCF248 or given IgG control. Mice treated with α-SCF248 had a decreased incidence of diarrhea and no reduction in body temperature suggesting a reduction in anaphylaxis compared to IgG control treated animals. Re-stimulated mesenteric lymph nodes indicated that α-SCF248 treated mice had decreased OVA-specific Th2 cytokine production compared to IgG control treated allergic animals. The reduction of food induced anaphylaxis was accompanied by a significant reduction in gut leak. The mesenteric lymph node cells were analyzed by flow cytometry and showed a decrease in the number of type 2 innate lymphoid cells in mice injected with α-SCF248. Morphometric enumeration of esterase+ mast cells demonstrated a significant reduction throughout the small intestine. Using a more chronic model of persistent food-induced anaphylaxis, short term therapeutic treatment with α-SCF248 during established disease effectively blocked food induced anaphylaxis. Together, these data suggest that therapeutically blocking SCF248 in food allergic animals can reduce the severity of food allergy by reducing mast cell mediated disease activation.

Indexed as

AllergensAnaphylaxisAnimalsAntibodies, MonoclonalAntibodies, NeutralizingBiomarkersBiopsyChemokine CCL2Disease Models, AnimalFemaleFood HypersensitivityImmunoglobulin EImmunophenotypingIntestinal MucosaMast CellsMiceAllergensAntibodies, MonoclonalAntibodies, NeutralizingBiomarkersChemokine CCL2Immunoglobulin EStem Cell Factoranaphylaxisfood allergyinnate lymphoid cellmast cellstem cell factor

Identifiers

PMID33786039
PMCPMC8005333
OpenAlexW3134338979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.